<DOC>
	<DOC>NCT00908271</DOC>
	<brief_summary>The purpose of this study is to estimate the absolute oral bioavailability of dapagliflozin.</brief_summary>
	<brief_title>Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Healthy male subjects (ages 18 to 45) as determined by medical history, physical examination, 12lead electrocardiogram (ECG), and clinical laboratory evaluations will be eligible to participate in the study Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations Participation in a radiolabeled investigational study drug trial within 12 months prior to admission to the clinical facility Exposure to significant radiation within 12 months prior to admission to the clinical facility</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>